Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

Global Regenerative Medicines Bone and Joints Research Report 2023: Increasing Product Approvals and Launches & R&D for Stem and Gene Therapies Bodes well for the Sector


DUBLIN, June 8, 2023 /PRNewswire/ -- The "Regenerative Medicines: Bone and Joint Applications" report has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo


The global market for regenerative medicine for bone and joint applications was valued at $9.6 billion in 2022.

By technology, this market is segmented into biomaterials, stem cell therapy, and tissue engineering. The tissue engineering segment recorded $2.4 billion in revenue in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 13.3% during the forecast period.

This study looks at most of the systems affected by factors such as R&D spending and increasing competition and new technologies. This report also covers merger and acquisition strategies and collaborations, as well as the strengths and weaknesses of each strategy type. The report provides information to all market players, potential entrants, government agencies, and other interested parties.

Regenerative medicine is an emerging technology that is set to revolutionize healthcare. Regenerative medicine aims to develop processes and methods to regrow, regenerate or repair diseased or damaged cells, tissues, or organs.

The rapid growth rate of the tissue engineering segment is attributed to the growing adoption of products designed and developed for treating tissues such as bone, skeletal muscle, cartilage, blood vessel, nerve tissue, skin, and for complete organs. According to the American Academy of Orthopedic Surgeons (Annual Report 2022), hip and knee arthroplasty procedures continue to increase.

The market for regenerative medicine for bone and joint applications is expected to display substantial growth during the forecast period, supported by an increasingly aging population worldwide, the growing occurrence of arthritic conditions such as osteoporosis and osteoarthritis, and an increasing number of orthopedic surgeries.

According to WHO, osteoporosis affects approximately 6.3% of men over the age of 50 and 21.2% of women over the same age range globally. According to International Osteoporosis Foundation, by 2050, the worldwide incidence of hip fracture in men is projected to increase by 310% and 240% in women, compared to 1990.

The market has been established in North America and Europe, which currently are the leaders in revenue sharing. However, the growth opportunities are better in emerging economies, especially Brazil, Russia, India, and China (BRIC) nations, due to an increased level of awareness as well as an increase in per capita income. Moreover, the increased focus of manufacturers toward emerging economies and innovative formulas to sell in emerging markets are further boosting the market's growth.

The major players in the market are Smith & Nephew, DePuy Synthes, Medtronic plc, Stryker Corp., Bioventus, Zimmer Biomet, Anika Therapeutics, Baxter, and CONMED Corp.

Report Includes

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Emerging/Upcoming Technologies in the Market

Chapter 5 Market Dynamics

Chapter 6 Market Breakdown by Technology

Chapter 7 Market Breakdown by Application

Chapter 8 Market Breakdown by Region

Chapter 9 Regulatory Aspects

Chapter 10 Patent Review/New Developments

Chapter 11 Competitive Landscape

Chapter 12 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/wj5qdb

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: